Sound Shore Management, an investment management firm, has released its investor letter for the fourth quarter of 2024. A ...

The financial results were actually positive, at the higher end of analysts' forecasts, but profit guidance for 2025 ...

If Axsome doesn’t, Teva can enter the U.S. market with its copy on Sept. 30, 2038. Auvelity is one of three drugs Axsome sells and by far the company’s top product. Auvelity combines a form of ...

Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be competitive with other Crohn’s, colitis medicines in testing.

Teva Pharmaceutical is one of the ... enjoy commercial success in the field. New products, including Ajovy, Austedo, and Uzedy, will fuel Teva's top and bottom lines as their adoption increases.

The U.S. Food and Drug Administration (FDA) has approved SELARSDI™ (ustekinumab-aekn), a biosimilar to Stelara® (ustekinumab), for treating various conditions including plaque psoriasis ...

In October 2024, the FDA approved the biosimilar SELARSDI™ (ustekinumab-aekn), manufactured by Teva Pharmaceuticals ... commercialize additional pharmaceutical products; our ability to ...

Under the agreement, Axsome will grant Teva a license to sell its generic version of Auvelity beginning on or after March 31, 2039, if pediatric exclusivity is granted for Auvelity, or on or after ...

In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI for all indicationsmatching the reference product Stelara ... (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S ...